|
Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008. ==Indications== Micafungin is indicated for the treatment of candidemia, acute disseminated candidiasis, ''Candida'' peritonitis, abscesses and esophageal candidiasis. Since January 23, 2008, micafungin has been approved for the prophylaxis of ''Candida'' infections in patients undergoing hematopoietic stem cell transplantation (HSCT). Micafungin works by way of concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, which is an essential polysaccharide comprising one-third of the majority of ''Candida'' spp. cell walls. This decreased glucan production leads to osmotic instability and thus cellular lysis. 〔Pappas PG, Rotstein CM, Betts RF, et al, “Micafungin Versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis,” Clin Infect Dis, 2007, 45(7):883-93. (17806055 )〕 〔Pettengell K, Mynhardt J, Kluyts T, et al, “Successful Treatment of Oesophageal Candidiasis by Micafungin: A Novel Systemic Antifungal Agent,” Aliment Pharmacol Ther, 2004, 20(4):475-81. (15298643 )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Micafungin」の詳細全文を読む スポンサード リンク
|